VRCA
Verrica Pharmaceuticals Inc
4.10$
-1.7%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 64.5% | 102.3% | 2.0% | 4,544.1% | 183.8% | 74.7% | 5.0% | 1,034.6% | 29.7% | 10.5% | – | 181.7% | 12.3% | 3.9% | 7.7% | 27.5% | 17.7% | 15.0% | 14.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | – | – | – | 35.5% | -2.3% | 98.0% | -4,444.1% | -83.8% | 25.3% | 95.0% | -934.6% | 70.3% | 89.5% | – | -81.7% | 87.7% | 96.1% | 92.3% | 72.5% | 82.3% | 85.0% | 85.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 44.7% | – | – | – | 567.3% | 1,842.5% | 33.4% | 4,452.9% | 7,402.7% | 3,145.6% | 223.2% | 267.6% | 129.3% | 64.1% | – | 339.2% | 66.4% | 14.5% | 15.4% | 49.5% | 76.8% | 102.9% | 48.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 54.8% | – | – | – | 1,187.5% | 2,417.3% | 47.2% | 20,905.9% | 11,673.0% | 3,262.1% | 687.5% | 854.7% | 387.8% | 297.9% | – | 1,797.2% | 248.6% | 69.7% | 65.6% | 167.9% | 198.9% | 176.5% | 126.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 99.5% | – | – | – | 1,754.8% | 4,259.8% | 80.6% | 4,689.7% | 19,075.7% | 6,407.7% | 914.9% | 229.2% | 556.4% | 383.3% | – | 3,235.2% | 324.1% | 84.2% | 80.9% | 208.9% | 275.7% | 308.4% | 178.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.5% | – | – | – | -1,719.3% | -4,262.1% | 17.4% | -9,133.8% | -19,159.5% | -6,382.4% | -819.9% | -1,163.8% | -486.1% | -293.7% | – | -3,316.9% | -236.4% | 11.9% | 11.3% | -136.4% | -193.4% | -223.4% | -92.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 8.6% | – | – | – | 251.0% | 498.1% | 1.0% | 83.8% | 1,351.4% | 0.0% | 56.8% | 115.9% | 60.6% | 45.7% | – | 682.8% | 64.1% | 16.8% | 14.6% | 25.8% | 3.2% | 2.8% | 12.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7.8% | – | – | – | -1,965.2% | -4,751.4% | 1.0% | -8,723.5% | -17,808.1% | -6,038.5% | -850.3% | -1,238.1% | -531.4% | -332.0% | – | -4,709.9% | -283.3% | 1.6% | -1.9% | -158.6% | -192.8% | -224.4% | -102.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.3% | – | – | – | 245.9% | 489.3% | 1.0% | -413.2% | -1,351.4% | 344.0% | -12.1% | 11.4% | 7.8% | – | – | -86.3% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7.8% | – | – | – | -1,965.2% | -4,751.4% | 1.0% | -8,723.5% | -17,808.1% | -6,038.5% | -850.3% | -1,238.1% | -531.4% | -332.0% | – | -4,709.9% | -283.3% | 1.6% | -1.9% | -158.6% | -192.8% | -224.4% | -102.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.3% | – | – | – | -1,691.4% | -4,207.5% | 5.8% | -8,530.9% | -17,262.2% | -5,924.7% | -786.3% | -1,028.6% | -461.9% | -279.8% | – | -3,953.5% | -213.2% | 19.9% | 14.0% | -129.0% | -185.7% | -221.3% | -88.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.